Company Long-Term Loans and Borrowings: NRx Pharma (NRXP)

Public company logo of NRx Pharma (NRXP)

The current NRx Pharmaceuticals (NRXP) share price chart on the GURU.Markets platform reflects the company's dynamics, as management is currently implementing crisis management measures to refresh its development portfolio and regain market confidence. Market capitalization relies on medical trial stages, while the 0.00 metric captures the absence of a consistent cash flow. The business is based on creating unique treatments for severe pneumonia and suicidal states.

NRXP NRx Pharmaceuticals Company Long-Term Debts (07/04/2022 - 10/31/2026)

Summary analytical data breakdowns for NRx Pharma (NRXP)

- market price and analyst price targets:
Stock Price nrxpharma.com|NRXP - Price Target Chart
- company stock exchange capitalization indicators:
Market Value NRx Pharmaceuticals|NRXP - Total Company Value
- book capitalization information:
Accounting Value per Share NRx Pharmaceuticals|NRXP - Book Capitalization|Market Capitalization to Book Value Ratio nrxpharma.com|NRXP - Cumulative Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio NRx Pharmaceuticals|NRXP - Long-Term Debt to Equity|Current Liabilities to Equity NRx Pharmaceuticals, Inc|NRXP - Company Debts|Debts to Net Assets NRx Pharmaceuticals|NRXP - Company Long-Term Liabilities|Short-Term Debt NRx Pharmaceuticals|Quick Liquidity Indicator nrxpharma.com
- earnings and multiples data:
NRXP - Net Profit
Analysis of all company metrics:NRXP nrxpharma.com
Brand item of NRx Pharmaceuticals Inc.

Conservative fundamental analysis of NRx Pharmaceuticals (NRXP) requires strict monitoring of the credit load to assess business resilience. This indicator aggregates all confirmed long-term liabilities, allowing for an evaluation of the company's financial autonomy through its long-term debt status, which is critical when developing costly psychiatric drugs and realizing the pricing power potential of innovative molecules.

Competitor analysis for NRx Pharmaceuticals

Company Long-Term Debts alkermes.com ALKS|AVDL - Company Long-Term Debt|Company Long-Term Loans and Borrowings ATAI (atai Life Sciences NV)|GH Research Corp (GHRS) - Company Long-Term Debt|Company Long-Term Liabilities Mind Medicine Corp|CMPS (COMPASS Pathways plc) - Company Long-Term Debts|Company Long-Term Debts lbpharma.us|Company Long-Term Liabilities DRUG (Bright Minds Biosciences Inc.)|VNDA (Vanda Pharma) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Cybin CYBN|ANRO (Alto Neuroscience Corp) - Long-Term Liabilities|CING - Company Long-Term Debt|Long-Term Debt Volume silopharma.com SILO|CPHI (chinapharmaholdings.com) - Company Long-Term Liabilities|Long-Term Debt Clearmind Medicine, Inc. (CMND)|PBM (Psyence Biomedical Limited) - Company Long-Term Debts|Company Long-Term Liabilities SciSparc Corp (SPRC)|Company Long-Term Debts SEEL|VRPX (virpaxpharma.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Karuna Therapeutics, Inc. KRTX